Boğa, CanBolaman, ZahitÇağırgan, SeçkinKaradoğan, İhsanÖzcan, Mehmet AliSaba, RabinSönmez, MehmetŞenol, EsinAkan, HamdiAkova, Murat2024-02-192024-02-192015Boğa, C. vd. (2015). "Recommendations for risk categorization and prophylaxis of invasive fungal diseases in hematological malignancies: A critical review of evidence and expert opinion (TEO-4)". Turkish Journal of Hematology, 32(2), 100-117.1300-7777https://doi.org/10.4274/tjh.2014.0277https://jag.journalagent.com/tjh/pdfs/TJH_32_2_100_117.pdfhttps://hdl.handle.net/11452/39853This is the last of a series of articles on invasive fungal infections prepared by opinion leaders in Turkey. The aim of these articles is to guide clinicians in managing invasive fungal diseases in hematological malignancies and stem cell transplantation based on the available best evidence in this field. The previous articles summarized the diagnosis and treatment of invasive fungal disease and this article aims to explain the risk categorization and guide the antifungal prophylaxis in invasive fungal disease.eninfo:eu-repo/semantics/openAccessHematologyHematological malignancyInvasive fungal infectionsProphylaxisRiskStem-cell transplantationReceiving antifungal prophylaxisBone-marrow-transplantationPlacebo-controlled trialDouble-blind trialCancer-patientsMold infectionsSingle-centerPulmonary aspergillosisFluconazole prophylaxisAntifungal agentsAntineoplastic agentsCross infectionDisinfectionFebrile neutropeniaHematologic neoplasmsHumansImmunocompromised hostImmunosuppressive agentsInvasive fungal infectionsOpportunistic infectionsPractice guidelines as topicRisk assessmentSecondary preventionTransplantation conditioningArticle0003691162000012-s2.0-8493074391910011732226316478HematologyAntifungal agents; Posaconazole; MicafunginAlemtuzumabAmphotericin B deoxycholateAmphotericin B lipid complexAnidulafunginAnthracyclineCaspofunginCell surface proteinCorticosteroidCytochrome P450 isoenzymeDiphtheria toxoid CRM197EchinocandinFluconazoleFructose bisphosphate aldolaseGlucan glucosidaseGlucuronoxylomannanItraconazoleLaminaranMalate dehydrogenaseMannanMicafunginPlaceboPosaconazoleRapamycinRecombinant proteinRituximabSignaling lymphocyte activation molecule associated proteinTriazoleUnindexed drugVincristineVoriconazoleAntifungal agentAntineoplastic agentImmunosuppressive agentAcute myeloblastic leukemiaAllogeneic stem cell transplantationCryptococcosisDisease associationDrug monitoringGraft versus host reactionHematologic malignancyHumanInfection riskInvasive aspergillosisInvasive candidiasisMass spectrometryMeta analysis (topic)MycosisMyelodysplastic syndromeRandomized controlled trial (topic)ReviewRisk assessmentTreatment outcomeAdverse effectsBloodChemically inducedComplicationCross infectionDisinfectionFebrile neutropeniaHematologic neoplasmsImmunocompromised patientInvasive fungal infectionsOpportunistic infectionsPractice guidelineProceduresSecondary preventionTransplantation conditioning